Efficacy and safety of esketamine hydrochloride adjunct to sufentanil in non-surgical patients under mechanical ventilation in the ICU (SENSATION trial): protocol for a multicentre, single-blind, randomised controlled trial.
BMJ open September 25, 2024 Yi Long, Donghuang Hong, Haibin Ni et al. 1 citation
Esketamine as an adjunct to sufentanil may reduce opioid consumption in non-surgical patients receiving mechanical ventilation in the ICU. This ongoing multicenter, single-blind, randomized controlled trial in six ICUs in China will assign 132 patients to either standard care (sufentanil alone) or an esketamine infusion at 0.2 mg/kg/hour plus sufentanil. The primary outcome is mean hourly sufentanil consumption. The trial aims to provide evidence for esketamine's efficacy and safety, addressing a gap in knowledge for this patient population.